PepGen shares more than double after muscle disease drug shows promise in trial

PepGen

25/09/2025 11:07

** Shares of drug developer PepGen PEPG.O rise 130% to $6.10 premarket

** Co said late on Wednesday its experimental drug, PGN-EDODM1, helped fix a key issue in patients with a muscle disease by improving how their cells process genetic instructions

** The drug was being tested in an early-stage trial as a potential treatment for myotonic dystrophy type 1, a genetic condition that causes muscles to weaken and stiffen, and can also affect the heart and lungs

** PepGen believes that correcting faulty RNA splicing could help reverse symptoms like muscle weakness and stiffness

** As of last close, stock down 29.8% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))